V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160017505 | 160013697 | 1.66 | 60.5 | Palliative (P) | 2019-02-14 | 2019-02-19 | ETOP 13-18 BEAT-meso Trial | 02 | N | EW EUROEWING 2012 ARM B IE | 101717240 |
| 160017510 | 160013698 | 1.57 | 59.5 | null | 2020-02-20 | 2020-05-29 | CARBOPLATIN + ETOPOSIDE | 02 | null | DACARBAZINE | 100415692 |
| 160017514 | 160013700 | 0 | 72.4 | null | null | 2019-05-14 | NB Rel CCLG guidelines Cyclo-Topotecan | 02 | null | MELPHALAN | 101654162 |
| 160017517 | 160013701 | 1.56 | 111.25 | Palliative (P) | 2016-11-29 | 2016-12-17 | Trial Unspecified | N | N | DOXORUBICIN + IFOSFAMIDE | 100509910 |
| 160017523 | 160013702 | 1.82 | 90 | null | 2015-12-20 | 2016-02-10 | Rituximab | null | null | CARBOPLATIN + VINORELBINE | 101634920 |
| 160017527 | 160013703 | 1.56 | 78.8 | Palliative (P) | 2019-10-23 | 2019-11-03 | Ifosfamide | 02 | null | CISPLATIN | 100500675 |
| 160017529 | 160013704 | 0 | 20 | Palliative (P) | 2016-02-14 | 2016-07-07 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | N | TRIAL | 101638514 |
| 160017538 | 160013705 | 0 | 63.1 | Curative (C) | 2017-06-23 | 2017-06-27 | IVA | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101583613 |
| 160017541 | 160013706 | 1.67 | 31 | Palliative (P) | 2021-12-06 | 2022-01-07 | MELPHALAN | 02 | N | LENALIDOMIDE | 101510823 |
| 160017546 | 160013707 | null | 84.4 | Palliative (P) | 2019-04-17 | 2019-10-16 | Gemcitabine day 1&8 | 02 | N | IPILIMUMAB + NIVOLUMAB | 100868010 |
| 160017548 | 160013708 | 0 | 82.2 | Adjuvant (A) | 2016-08-01 | 2016-08-31 | Cisplatin + Etoposide (3 day) | 02 | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 100915208 |
| 160017550 | 160013709 | 1.54 | 36.5 | Palliative (P) | 2019-03-30 | 2019-04-06 | CONFIRM TRIAL | Y | N | IPM | 101050889 |
| 160017553 | 160013710 | 1.63 | 72.8 | Adjuvant (A) | 2019-03-23 | 2019-08-17 | Doxorubicin + Ifosfamide | N | N | IRINOTECAN + TEMOZOLOMIDE | 101205099 |
| 160017554 | 160013711 | 1.72 | 103 | null | 2019-09-03 | 2019-11-28 | Cisplatin + Etoposide po | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101244428 |
| 160017555 | 160013712 | 0 | 44.5 | null | 2019-09-10 | 2019-09-14 | GemCarbo Days 1+8 | 02 | null | NB HRNBL-1 COJEC IND COURSE B | 100460495 |
| 160017556 | 160013713 | 1.76 | 74 | null | 2019-06-29 | 2019-11-16 | GEMCITABINE | 02 | null | IFOSFAMIDE | 101502820 |
| 160017558 | 160013714 | null | 75.3 | Adjuvant (A) | 2019-08-29 | 2019-09-26 | Ifosfamide | 02 | N | ETOPOSIDE | 101162573 |
| 160017563 | 160013715 | null | 84 | null | 2019-06-17 | 2019-06-17 | null | 02 | null | IPILIMUMAB + NIVOLUMAB | 100927757 |
| 160017564 | 160013716 | 1.72 | 71 | 03 | 2018-09-25 | 2019-01-17 | STS Non-Rhabdo EpSSG 2005 IVA | 02 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101163188 |
| 160017565 | 160013717 | 0 | 36.5 | null | null | 2019-08-17 | ETOPOSIDE | 02 | null | PEMBROLIZUMAB | 101024383 |
| 160017566 | 160013718 | 1.69 | 57.45 | Neo-adjuvant (N) | null | 2017-08-06 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 100452181 |
| 160017571 | 160013719 | 1.81 | 73.8 | null | 2019-01-05 | 2019-02-01 | Niraparib | 01 | null | CAPECITABINE | 101033478 |
| 160017572 | 160013720 | 0 | 75.8 | null | 2018-01-28 | 2018-01-29 | STS Rhabdomyosarcoma RMS 2005 VA | 02 | null | EW EUROEWING 2012 ARM A VAC | 100013877 |
| 160017573 | 160013721 | 0 | 61.6 | null | 2016-04-26 | 2016-05-11 | Palbociclib | 02 | null | VINCRISTINE | 100093601 |
| 160017574 | 160013722 | 0 | 67.25 | Curative (C) | 2018-09-25 | 2018-09-27 | Doxorubicin + Ifosfamide | 02 | null | IRINOTECAN + TEMOZOLOMIDE | 100429582 |
| 160017579 | 160013723 | 1.72 | 34.4 | null | null | 2016-05-14 | Gemcitabine day 1&8 | 02 | null | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 100917943 |
| 160017581 | 160013724 | 1.59 | 74.8 | null | null | 2016-10-15 | NB HRNBL-1 Isotretinoin | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 101161754 |
| 160017582 | 160013725 | 0 | 48.9 | Palliative (P) | 2019-07-26 | 2019-08-01 | ATOMIC-MESO TRIAL | 02 | N | CISPLATIN + ETOPOSIDE | 101358586 |
| 160017585 | 160013726 | 1.68 | 80 | null | 2021-09-18 | 2021-09-18 | STS Rhabdomyosarco RMS 2005 IVADoVV | 2 | null | IPILIMUMAB + NIVOLUMAB | 101799693 |
| 160017587 | 160013728 | 1.9 | 80 | null | 2018-06-06 | 2019-08-24 | EW EuroEwing 2012 Arm A VAC | null | null | ETOP 13-18 BEAT-MESO TRIAL | 100950735 |
| 160017589 | 160013729 | null | 55 | null | 2016-06-04 | 2016-08-12 | Melphalan + Treosulfan - HD | 02 | null | DACTINOMYCIN + CYCLO + VINCRISTINE | 101010455 |
| 160017598 | 160013730 | null | 61 | Palliative (P) | 2018-12-07 | 2019-01-19 | PEMBROLIZUMAB | 01 | null | STS RHABDO VIT0910 VINC IRINO TEMOZ | 101167241 |
| 160017604 | 160013731 | 1.79 | 41 | null | 2017-10-13 | 2018-07-14 | NB Rel GD2ch14.18/CHO, IL-2 Isotret | 02 | null | EW REL REECUR IRINOTECAN/TEMOZOLOMIDE | 101663511 |
| 160017607 | 160013732 | 1.82 | 11.5 | null | 2016-06-20 | 2017-12-27 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 100578964 |
| 160017610 | 160013733 | 1.74 | 68 | null | 2018-12-18 | 2019-01-23 | NB HRNBL-1 COJEC Ind COURSE A | 02 | null | ETOP 13-18 BEAT-MESO TRIAL | 100706943 |
| 160000286 | 160013734 | 1.63 | 16.3 | Adjuvant (A) | 2017-08-19 | 2017-08-20 | MELPHALAN | 02 | N | IFOSFAMIDE | 100422236 |
| 160000338 | 160013735 | 1.71 | 90.3 | Neo-adjuvant (N) | 2020-02-11 | 2020-02-16 | DACTINOMYCIN + CYCLO + VINCRISTINE | 02 | N | PEMBROLIZUMAB | 100434819 |
| 160000825 | 160013738 | 1.7 | 115.65 | Curative (C) | 2021-03-14 | 2021-03-24 | IPILIMUMAB + NIVOLUMAB | 02 | N | ETOPOSIDE + IFOSFAMIDE | 100904085 |
| 160000895 | 160013739 | 1.1 | 19 | null | 2019-02-21 | 2019-07-17 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | null | NB LOW/INTERMED RISK GUIDELINES CADO | 100855895 |
| 160000937 | 160013740 | 1.64 | 67.5 | Adjuvant (A) | 2019-04-20 | 2019-05-05 | Trial Unspecified | Y | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100945451 |
| 160001486 | 160013741 | 1.6 | 68 | null | 2020-01-02 | 2020-01-04 | null | 02 | null | NB HRNBL-1 BUMEL MAT | 101068815 |
| 160001510 | 160013742 | 1.58 | 100 | null | 2020-08-27 | 2020-08-28 | PROMISE-MESO TRIAL | 02 | null | EW REL REECUR TOPOTECAN/CYCLOPHOSPHAMIDE | 101365304 |
| 160001576 | 160013743 | 1.64 | 13 | null | 2016-05-13 | 2017-03-23 | Doxorubicin + Ifosfamide | 02 | null | NB HRNBL-1 COJEC IND COURSE C | 101069483 |
| 160001840 | 160013744 | 0 | 64.1 | Curative (C) | 2019-05-15 | 2019-05-31 | ETOP 13-18 BEAT-meso Trial | Y | N | OLAPARIB | 100537037 |
| 160001867 | 160013745 | 1.6 | 21 | Palliative (P) | null | 2018-07-23 | Cyclophosphamide + Vincristine | N | N | EW EUROEWING 2012 ARM B VC | 100608098 |
| 160001933 | 160013746 | 1.72 | 75 | Palliative (P) | 2017-05-10 | 2017-05-15 | IRINOTECAN + VINCRISTINE | N | N | CISPLATIN + DOXORUBICIN + METHOTREXATE | 100731289 |
| 160002009 | 160013747 | 1.66 | 19.6 | Curative (C) | 2020-01-11 | 2020-01-11 | MESO-02 TRIAL | 02 | null | EURO-EWING | 100169851 |
| 160002514 | 160013748 | 1.7 | 12.7 | null | 2017-03-24 | 2017-05-04 | Temozolomide + RT | null | null | ETOPOSIDE | 101490250 |
| 160002663 | 160013749 | 0 | 114.6 | null | 2019-12-06 | 2020-01-22 | VAI (Ifos 3g/m2) | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100494391 |
| 160003333 | 160013750 | 1.6 | 86.8 | null | 2019-11-22 | 2019-12-27 | NB HRNBL-1 BUMEL MAT | 02 | null | CARBOPLATIN + LIPOSOMAL DOX | 101395089 |